Filing Flows › Companies › Idexx Laboratories › Timeline
Idexx Laboratories stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−5.3% to $676.04
Idexx Laboratories (IDXX) stock fell 5% over the last 252 sessions, to $676.04. On the way it reported 4 quarters, its insiders filed 5 open-market trades and 6 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Form 144 | Form 144: Michael J Lane plans to sell $2.7M | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Sharon E Underberg plans to sell $6.1M | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Jonathan J Mazelsky plans to sell $17.7M | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Daniel M Junius plans to sell $346K | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Daniel M Junius plans to sell $840K | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Insider sale | Junius Daniel M sold $494K | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Insider sale | Lane Michael sold $167K | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Insider sale | Mazelsky Jonathan Jay sold $1.4M | +3.9% (+2.2% vs SPY) | — | — |
| Nov 4, 2026 | Insider sale | Underberg Sharon E. sold $4.4M | +3.9% (+2.2% vs SPY) | — | — |
| Nov 2, 2026 | Earnings | Earnings: beat the EPS estimate by 8.0% | +19.8% (+20.2% vs SPY) | +20.4% (+23.2% vs SPY) | — |
| Sep 4, 2026 | Form 144 | Form 144: Lawrence D Kingsley plans to sell $1.2M | +1.1% (+1.5% vs SPY) | −4.8% (−3.6% vs SPY) | −0.4% (−0.9% vs SPY) |
| Sep 4, 2026 | Insider sale | Kingsley Lawrence D sold $1.2M | +1.1% (+1.5% vs SPY) | −4.8% (−3.6% vs SPY) | −0.4% (−0.9% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: beat the EPS estimate by 8.5% | +3.5% (+1.7% vs SPY) | +4.8% (+2.8% vs SPY) | −4.1% (−4.6% vs SPY) |
| May 5, 2026 | Earnings | Earnings: beat the EPS estimate by 1.7% | 0.0% (−0.8% vs SPY) | −5.7% (−8.6% vs SPY) | −0.4% (−5.4% vs SPY) |
| Mar 26, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.4% (+1.4% vs SPY) | −1.9% (−1.7% vs SPY) | −1.7% (−10.1% vs SPY) |
| Feb 13, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.5% (−0.7% vs SPY) | −1.0% (−1.1% vs SPY) | −7.0% (−5.3% vs SPY) |
| Feb 2, 2026 | Earnings | Earnings: beat the EPS estimate by 4.8% | −4.7% (−5.2% vs SPY) | −3.9% (−3.7% vs SPY) | −5.3% (−3.6% vs SPY) |
| Jan 13, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.5% (−1.3% vs SPY) | −5.5% (−2.9% vs SPY) | −11.1% (−10.6% vs SPY) |
| Nov 13, 2025 | 8-K | Material definitive agreement | −1.7% (−1.6% vs SPY) | −1.8% (+1.2% vs SPY) | −0.2% (−1.4% vs SPY) |
Insiders’ record here
In the year on the chart, Idexx Laboratories' insiders reported 0 open-market buys ($0) and 5 sales ($7.6M).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Idexx Laboratories: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.